Alnylam Pharmaceuticals

Sustainability Report and Carbon Intensity Rankings

Is Alnylam Pharmaceuticals doing their part?

Their DitchCarbon score is 47

Alnylam Pharmaceuticals has a DitchCarbon Score of 47 out of 100, indicating a moderate level of sustainability in their operations. This score suggests that the company’s carbon intensity is relatively high, implying there is significant room for improvement in reducing emissions. Efforts to lower their carbon intensity would enhance their sustainability profile and contribute to better environmental performance.

This was calculated based on 30+ company specific emissions data points, the higher the score, the better. Check out our methodology.

Industry emissions intensity

Very low

Low

Medium

High

Very high

Alnylam Pharmaceuticals is part of the industrial manufacturing sector, which has a carbon intensity ranking of very low. Some industries are more damaging than others, this ranking gives you an indication of how carbon intensive the industry is which this company operates in.

Location emissions intensity

Very low

Low

Medium

High

Very high

Alnylam Pharmaceuticals, based in the United States, benefits from the country’s low carbon intensity rating. This favorable environmental context supports the company’s sustainability efforts by reducing its carbon footprint.
5.71%

...this company is doing 5.71% better in emissions than the industry average.

Alnylam Pharmaceuticals, founded in 2002 and headquartered in Cambridge, Massachusetts, operates within the biopharmaceutical industry. The company specializes in the development of RNAi therapeutics, a novel class of medicines aimed at treating rare diseases. With a global presence and a robust clinical development pipeline, Alnylam is dedicated to advancing new treatments for patients in need.

Bad news, Alnylam Pharmaceuticals hasn't committed to SBTi goals yet

Alnylam Pharmaceuticals has not yet established specific commitments with the Science Based Targets initiative (SBTi). This means the company is still in the process of defining clear, science-based emissions reduction targets to align with global efforts to mitigate climate change.

There’s always room for improvement,

DitchCarbon recommends...

Alnylam Pharmaceuticals should consider promoting behavioral changes among its workforce to minimize emissions, which could potentially reduce their Scope 1 emissions by 15%.
Not participating

Meet our 360 emissions intelligence platform

✓ Comprehensive database of calculators, life cycle analysis, carbon footprints of companies

✓ Peer group, recommended actions, historical reports, data sources

✓ Complete Scope 1-2-3 data, emission factors, yearly breakdown

✓ Complete SBTi and CDP status with sources

✓ Company emission source URLs

✓ Supply level emission factors

30+ emissions data points on millions of companies

✓ Comprehensive database of calculators, life cycle analysis, carbon footprints of companies

✓ Peer group, recommended actions, historical reports, data sources

✓ Complete Scope 1-2-3 data, emission factors, yearly breakdown

✓ Complete SBTi and CDP status with sources

✓ Company emission source URLs

✓ Supply level emission factors

Claim this profile

Are you associate with this company?
Help us improve our data and claim this profile.

Our methodology

Read about our emission calculation methodologies, and what the DitchCarbon Score means.